Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation

Cancer

Volumn 116, Issue 21, 2010, Pages 5001-5011

  Dodero, Anna ^a   Crocchiolo, Roberto ^b   Patriarca, Francesca ^c   Miceli, Rosalba ^a   Castagna, Luca ^d   Ciceri, Fabio ^b   Bramanti, Stefania ^d   Frungillo, Niccolo ^a   Milani, Raffaella ^a   Crippa, Flavio ^a   Fallanca, Federico ^b   Englaro, Emanuela ^c   Corradini, Paolo ^a,e  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Aggressive non Hodgkin lymphoma; Allogeneic transplantation; Hodgkin lymphoma; Positron emission tomography

Indexed keywords

ALEMTUZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; NAVELBINE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; THIOTEPA; TREOSULFAN; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE FREE SURVIVAL; DONOR; FOLLOW UP; GRAFT VERSUS HOST REACTION; HAZARD RATIO; HODGKIN DISEASE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; GRAFT VS HOST DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 78249273298     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25357     Document Type: Article

References (30)

1. Sureda A, Robinson S, Canals C, et al. Reduced intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008; 26: 455 -462.
2. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine melphalan as preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M. D. Anderson Cancer Center experience. Hematologica. 2008; 93: 257 -264.
3. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005; 365: 1934 -1941.
4. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002; 100: 4310 -4316.
5. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004; 104: 3865 -3871.
6. Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004; 22: 2172 -2176.
7. Le Gouill S, Milpied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francais de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol. 2008; 26: 2264 -2271.
8. Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia. 2007; 21: 2316 -2323.
9. Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood. 2007; 109: 486 -491.
10. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003; 102: 53 -59.
11. Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer. 2007; 109: 2481 -2489.
12. Dodero A, Carniti C, Raganato A, et al. Haploidentical stem cell transplantation following a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: post-transplant CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood. 2009; 113: 4771 -4779.
13. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation. 1974; 18: 295 -304.
14. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981; 57: 267 -276.
15. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999; 17: 1244 -1253.
16. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007; 25: 571 -578.
17. Marubini E, Valsecchi MG,. Analysing Survival Data for Clinical Trials and Observational Studies. Chichester, United Kingdom: John Wiley & Sons; 1995: 335 -344.
18. Gray RJ,. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141 -1154.
19. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496 -509.
20. Durrleman S, Simon R,. Flexible regression models with cubic splines. Stat Med. 1989; 8: 551 -561.
21. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005; 23: 1993 -2003.
22. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007; 25: 3746 -3752.
23. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR,. FDG-PET after 2 to 3 cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005; 16: 1514 -1523.
24. Yoshimi A, Izutsu K, Takahashi M, et al. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. Am J Hematol. 2008; 83: 477 -481.
25. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006; 12: 172 -183.
26. Dhedin N, Giraudier S, Gaulard P, et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societe Francaise de Greffe de Moelle. Br J Haematol. 1999; 107: 154 -161.
27. Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008; 112: 1992 -2001.
28. Farina L, Bruno B, Patriarca F, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or nonmyeloablative allogeneic stem cell transplantation. Leukemia. 2009; 23: 1131 -1138.
29. Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Hematologica. 2009; 94: 230 -238.
30. Baron F, Storb R, Storer BE, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol. 2006; 24: 4150 -4157.